FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169463348> ?p ?o ?g. }

• W2169463348 endingPage "1287" @default.
• W2169463348 startingPage "1274" @default.
• W2169463348 abstract "Abstract Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver cancer cells in vitro and in vivo. Experimental Design: Different liver cancer cell lines were exposed to sorafenib in the presence or absence of MPT0E028, and cell viability was determined by MTT assay. Effects of combined treatment on cell cycle and intracellular signaling pathways were assessed by flow cytometry and Western blot analysis. The Hep3B xenograft model was used to examine the antitumor activity in vivo. Results: Our data indicate that sorafenib and MPT0E028 synergistically reduced cell viability in liver cancer cells, and also markedly induced apoptotic cell death in these cells, as evidenced by the cleavage of caspase-3, PARP, and DNA fragmentation. MPT0E028 altered the global modifications of histone and nonhistone proteins regardless of the presence of sorafenib. However, sorafenib blocked MPT0E028-induced Erk activation and its downstream signaling cascades, such as Stat3 phosphorylation (Ser727) and Mcl-1 upregulation. Ectopic expression of constitutively active Mek successively reversed the apoptosis triggered by the combined treatment. Pharmacologic inhibition of Mek by PD98059 potentiated MPT0E028-induced apoptosis, suggesting that the synergistic interaction between MPT0E028 and sorafenib occurs at least partly through inhibition of Erk signaling. The data demonstrated that transcriptional activation of fibroblast growth factor receptor 3 (FGFR3) contributes to MPT0E028-mediated Erk phosphorylation. Finally, MPT0E028 plus sorafenib significantly improved the tumor growth delay (TGD) in a Hep3B xenograft model. Conclusions: These findings suggest that MPT0E028 in combination with sorafenib has significant anti-hepatocellular carcinoma activity in preclinical models, potentially suggesting a novel therapeutic strategy for patients with advanced hepatocellular carcinoma. Clin Cancer Res; 20(5); 1274–87. ©2014 AACR." @default.
• W2169463348 created "2016-06-24" @default.
• W2169463348 creator A5012824711 @default.
• W2169463348 creator A5016825023 @default.
• W2169463348 creator A5024894709 @default.
• W2169463348 creator A5053529693 @default.
• W2169463348 creator A5075967549 @default.
• W2169463348 creator A5080852182 @default.
• W2169463348 creator A5082735709 @default.
• W2169463348 creator A5084141354 @default.
• W2169463348 date "2014-03-01" @default.
• W2169463348 modified "2023-09-29" @default.
• W2169463348 title "Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells <i>In Vitro</i> and <i>In Vivo</i>" @default.
• W2169463348 cites W1966248219 @default.
• W2169463348 cites W1967018540 @default.
• W2169463348 cites W1967447165 @default.
• W2169463348 cites W1970060716 @default.
• W2169463348 cites W1971837077 @default.
• W2169463348 cites W1974342793 @default.
• W2169463348 cites W1978664410 @default.
• W2169463348 cites W1990532502 @default.
• W2169463348 cites W1991478260 @default.
• W2169463348 cites W1992034322 @default.
• W2169463348 cites W1994193851 @default.
• W2169463348 cites W1997326654 @default.
• W2169463348 cites W1997533142 @default.
• W2169463348 cites W2008897100 @default.
• W2169463348 cites W2012191027 @default.
• W2169463348 cites W2018902131 @default.
• W2169463348 cites W2019514608 @default.
• W2169463348 cites W2020002352 @default.
• W2169463348 cites W2020485312 @default.
• W2169463348 cites W2021172314 @default.
• W2169463348 cites W2021198013 @default.
• W2169463348 cites W2021983756 @default.
• W2169463348 cites W2023447208 @default.
• W2169463348 cites W2029148944 @default.
• W2169463348 cites W2035731408 @default.
• W2169463348 cites W2046379951 @default.
• W2169463348 cites W2046416127 @default.
• W2169463348 cites W2050512142 @default.
• W2169463348 cites W2053290453 @default.
• W2169463348 cites W2061345986 @default.
• W2169463348 cites W2065108275 @default.
• W2169463348 cites W2070396671 @default.
• W2169463348 cites W2080059014 @default.
• W2169463348 cites W2082777374 @default.
• W2169463348 cites W2103562758 @default.
• W2169463348 cites W2106787323 @default.
• W2169463348 cites W2107277218 @default.
• W2169463348 cites W2112439514 @default.
• W2169463348 cites W2114994872 @default.
• W2169463348 cites W2131217588 @default.
• W2169463348 cites W2144851362 @default.
• W2169463348 cites W2148718757 @default.
• W2169463348 cites W2156871508 @default.
• W2169463348 cites W2165804364 @default.
• W2169463348 cites W2166310425 @default.
• W2169463348 cites W2168227773 @default.
• W2169463348 cites W2171625872 @default.
• W2169463348 cites W2331221462 @default.
• W2169463348 cites W4245403358 @default.
• W2169463348 cites W58959379 @default.
• W2169463348 doi "https://doi.org/10.1158/1078-0432.ccr-12-3909" @default.
• W2169463348 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4284945" @default.
• W2169463348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24520095" @default.
• W2169463348 hasPublicationYear "2014" @default.
• W2169463348 type Work @default.
• W2169463348 sameAs 2169463348 @default.
• W2169463348 citedByCount "39" @default.
• W2169463348 countsByYear W21694633482014 @default.
• W2169463348 countsByYear W21694633482015 @default.
• W2169463348 countsByYear W21694633482016 @default.
• W2169463348 countsByYear W21694633482017 @default.
• W2169463348 countsByYear W21694633482018 @default.
• W2169463348 countsByYear W21694633482019 @default.
• W2169463348 countsByYear W21694633482020 @default.
• W2169463348 countsByYear W21694633482021 @default.
• W2169463348 countsByYear W21694633482022 @default.
• W2169463348 countsByYear W21694633482023 @default.
• W2169463348 crossrefType "journal-article" @default.
• W2169463348 hasAuthorship W2169463348A5012824711 @default.
• W2169463348 hasAuthorship W2169463348A5016825023 @default.
• W2169463348 hasAuthorship W2169463348A5024894709 @default.
• W2169463348 hasAuthorship W2169463348A5053529693 @default.
• W2169463348 hasAuthorship W2169463348A5075967549 @default.
• W2169463348 hasAuthorship W2169463348A5080852182 @default.
• W2169463348 hasAuthorship W2169463348A5082735709 @default.
• W2169463348 hasAuthorship W2169463348A5084141354 @default.
• W2169463348 hasBestOaLocation W21694633481 @default.
• W2169463348 hasConcept C104317684 @default.
• W2169463348 hasConcept C121608353 @default.
• W2169463348 hasConcept C126322002 @default.
• W2169463348 hasConcept C150903083 @default.
• W2169463348 hasConcept C185592680 @default.
• W2169463348 hasConcept C190283241 @default.
• W2169463348 hasConcept C207001950 @default.
• W2169463348 hasConcept C2776202225 @default.

• next